OnKure Therapeutics(OKUR)
$2.76-0.06 (-2.13%)
OKUR
OnKure Therapeutics financials statements
$2.76
At close:-0.06 (-2.13%)
Want to see OKUR full AI Analyst Report?
OnKure Therapeutics (OKUR) Ratios
441 Followers
OnKure Therapeutics Ratios
OKUR's free cash flow for Q3 2026 was $-13.11M. For the 2026 fiscal year, OKUR's free cash flow was decreased by $-32.00K and operating cash flow was $-13.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 |
| Quick Ratio | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 |
| Cash Ratio | 9.97 | 10.52 | 4.10 | 2.08 | 20.10 |
| Solvency Ratio | -9.89 | -4.69 | -0.25 | -0.41 | -5.83 |
| Operating Cash Flow Ratio | -8.75 | -4.85 | -4.74 | -4.86 | -6.12 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 54.91M | $ 101.92M | $ -103.81M | $ -56.79M | $ 146.92M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.02 | 0.04 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | -0.01 | -0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | -0.01 | -0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.11 | -0.35 | -0.29 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | -172.37 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | -181.29 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.10 | 0.05 | 0.05 | 0.00 |
| Net Debt to EBITDA | 1.00 | 2.12 | 0.84 | 0.37 | 3.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.55% | 96.85% | 95.61% | 99.15% | 99.88% |
| Return on Assets (ROA) | -95.81% | -45.84% | -98.82% | -184.46% | -25.82% |
| Return on Equity (ROE) | -105.93% | -50.73% | 34.67% | 54.23% | -27.02% |
| Return on Capital Employed (ROCE) | -112.02% | -52.11% | -129.83% | -284.65% | -26.94% |
| Return on Invested Capital (ROIC) | -110.93% | -51.84% | -128.88% | -280.60% | -26.94% |
| Return on Tangible Assets | -95.81% | -45.84% | -98.82% | -184.46% | -25.82% |
| Earnings Yield | -151.84% | -45.91% | -15.95% | -9.50% | -25.64% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.58 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -630.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 630.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.83 | -3.83 | -2.59 | -2.02 | -20.93 |
| Free Cash Flow Per Share | -3.84 | -3.84 | -2.61 | -2.11 | -21.04 |
| Dividend Paid and CapEx Coverage Ratio | -1126.70 | -983.02 | -140.43 | -23.77 | -191.83 |
| Capital Expenditure Coverage Ratio | -1126.70 | -983.02 | -140.43 | -23.77 | -191.83 |
| Operating Cash Flow Coverage Ratio | -94.40 | -47.11 | -51.26 | -42.31 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -132.34% | -44.60% | -15.71% | -9.04% | -24.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.66 | -2.18 | -6.27 | -10.53 | -3.90 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.70 | 1.10 | -2.17 | -5.71 | 1.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.76 | -2.24 | -6.36 | -11.07 | -4.06 |
| Price-to-Operating Cash Flow Ratio | -0.76 | -2.24 | -6.41 | -11.53 | -4.08 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | -0.04 | -0.31 | 0.12 | -0.02 |
| Enterprise Value Multiple | 0.33 | -0.10 | -5.53 | -10.21 | -0.77 |
| Enterprise Value | -19.30M | 5.04M | 192.23M | 299.90M | 30.47M |
| EV to EBITDA | 0.33 | -0.10 | -5.53 | -10.21 | -0.77 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.37 | -0.10 | -5.53 | -10.68 | -0.80 |
| EV to Operating Cash Flow | 0.37 | -0.10 | -5.56 | -11.13 | -0.80 |
| Tangible Book Value Per Share | 4.16 | 7.78 | -7.63 | -4.08 | 81.14 |
| Shareholders’ Equity Per Share | 4.16 | 7.78 | -7.63 | -4.08 | 81.14 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.40 | -3.95 | -2.65 | -2.21 | -21.92 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.01 | 1.00 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.87 | 0.97 | 0.98 | 0.91 | 0.96 |
Currency in USD

